Wygląda na to, że wystąpił błąd podczas próby wczytania tej strony.
Nasz zespół został powiadomiony, ale jeśli problem nie ustąpi, skontaktuj się z nami, korzystając z widżetu widżet e-mail wsparcia.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -65,2x - -72,1x | -68,6x |
| Selected Fwd EBIT Multiple | 32,0x - 35,4x | 33,7x |
| Fair Value | ₩2.771 - ₩3.100 | ₩2.935 |
| Upside | -26,9% - -18,2% | -22,5% |
| Benchmarks | Ticker | Full Ticker |
| JW Lifescience Corporation | A234080 | KOSE:A234080 |
| Kyung Dong Pharmaceutical Co., Ltd. | A011040 | KOSDAQ:A011040 |
| DAE HWA Pharmaceutical Co., Ltd. | A067080 | KOSDAQ:A067080 |
| Kukje Pharma Co., Ltd. | A002720 | KOSE:A002720 |
| BCWORLD PHARM. Co., Ltd. | A200780 | KOSDAQ:A200780 |
| KUKJEON PHARMACEUTICAL Co., Ltd | A307750 | KOSDAQ:A307750 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A234080 | A011040 | A067080 | A002720 | A200780 | A307750 | ||
| KOSE:A234080 | KOSDAQ:A011040 | KOSDAQ:A067080 | KOSE:A002720 | KOSDAQ:A200780 | KOSDAQ:A307750 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 3.8% | -36.1% | 3.2% | 3.8% | NM- | NM- | |
| 3Y CAGR | 8.1% | -45.0% | 26.9% | NM- | NM- | -60.8% | |
| Latest Twelve Months | 20.1% | 127.4% | 936.3% | 1488.7% | 289.5% | -173.4% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 16.5% | 2.0% | 3.1% | 1.8% | 0.5% | 3.3% | |
| Prior Fiscal Year | 14.9% | -15.3% | 1.4% | -1.5% | 8.5% | 5.3% | |
| Latest Fiscal Year | 16.1% | 1.4% | 4.5% | 4.3% | 2.0% | 0.3% | |
| Latest Twelve Months | 15.4% | 2.5% | 4.4% | 5.0% | 4.6% | -1.7% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 0.92x | 0.54x | 2.59x | 0.60x | 1.56x | 1.54x | |
| EV / LTM EBITDA | 4.1x | 11.4x | 30.0x | 8.7x | 10.5x | 71.3x | |
| EV / LTM EBIT | 6.0x | 22.0x | 59.0x | 12.0x | 34.4x | -88.8x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 6.0x | 22.0x | 59.0x | ||||
| Historical EV / LTM EBIT | 44.5x | 71.2x | 89.1x | ||||
| Selected EV / LTM EBIT | -65.2x | -68.6x | -72.1x | ||||
| (x) LTM EBIT | (2,337) | (2,337) | (2,337) | ||||
| (=) Implied Enterprise Value | 152,348 | 160,366 | 168,385 | ||||
| (-) Non-shareholder Claims * | (17,774) | (17,774) | (17,774) | ||||
| (=) Equity Value | 134,574 | 142,593 | 150,611 | ||||
| (/) Shares Outstanding | 50.1 | 50.1 | 50.1 | ||||
| Implied Value Range | 2,686.53 | 2,846.60 | 3,006.67 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 2,686.53 | 2,846.60 | 3,006.67 | 3,790.00 | |||
| Upside / (Downside) | -29.1% | -24.9% | -20.7% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A234080 | A011040 | A067080 | A002720 | A200780 | A307750 | |
| Enterprise Value | 224,350 | 104,730 | 380,940 | 101,027 | 117,830 | 207,623 | |
| (+) Cash & Short Term Investments | 27,291 | 33,420 | 6,780 | 12,537 | 5,631 | 34,269 | |
| (+) Investments & Other | 0 | 66,386 | 3,823 | 4,605 | 3,078 | 5,187 | |
| (-) Debt | (56,536) | (46,404) | (98,217) | (29,477) | (86,406) | (57,528) | |
| (-) Other Liabilities | 0 | (254) | (4,651) | (15) | (50) | 298 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 195,105 | 157,879 | 288,674 | 88,679 | 40,083 | 189,850 | |
| (/) Shares Outstanding | 15.5 | 26.9 | 17.5 | 20.4 | 8.4 | 50.1 | |
| Implied Stock Price | 12,600.00 | 5,860.00 | 16,480.00 | 4,355.00 | 4,750.00 | 3,790.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 12,600.00 | 5,860.00 | 16,480.00 | 4,355.00 | 4,750.00 | 3,790.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |